pubmed tirzepatide Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis Tirzepatide | C225H348N48O68 | CID
Description
one study found its effective in single, double doses, while another found it may cause more harm than good
It's not clear how long the process will take
Feldman, T., Foster, E., Glower, D
Here are several important considerations to keep in mind: FDA Approval : Currently, Tirzepatide (Mounjaro) is FDA-approved for the treatment of Type 2 diabetes, not specifically for weight loss
Your provider may reduce your dose or offer other solutions to help mitigate side effects that are bothersome to you
